Peptidyl prodrugs and linkers and stabilizers useful therefor
View Patent ↗The present invention provides analogues of duocarmycins that are potent cytotoxins. Also provided are peptidyl and disulfide linkers that are cleaved in vivo. The linkers are of use in forming prodrugs and conjugates of the cytotoxins of the invention as well as other diagnostic and therapeutic moieties. The invention provides prodrugs and conjugates of the duocarmycin analogues with the linker arms of the invention.
1. A compound having the structure:
or a pharmaceutically acceptable salt thereof;
wherein
X and Z are members independently selected from O, S and NR 23
wherein
R 23 is a member selected from H, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, and acyl;
R 1 is CO 2 CH 3 ;
R 2 is H, or substituted or unsubstituted lower alkyl;
R 11 is C(O)NR 12 R 13
in which
R 12 , and R 13 are members independently selected from H, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl and substituted or unsubstituted aryl, and at least one of R 12 and R 13 comprises a cleaveable group;
R 4 and R 5 are members independently selected from H, substituted or unsubstituted alkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocycloalkyl, halogen, NO 2 , NR 15 R 16 , NC(O)R 15 , OC(O)NR 15 R 16 , OC(O)OR 15 , C(O)R 15 , OR 15
wherein
R 15 and R 16 are independently selected from H, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocycloalkyl and substituted or unsubstituted peptidyl, wherein R 15 and R 16 together with the nitrogen atom to which they are attached are optionally joined to form a substituted or unsubstituted heterocycloalkyl ring system having from 4 to 6 members, optionally containing two or more heteroatoms; and
X 1 is a leaving group.
2. The compound according to claim 1 , wherein said leaving group is a member selected from azide, halogen, alkylsulfonyl and arylsulfonyl groups.
3. The compound according to claim 1 , wherein X 1 is Cl or Br.
4. A compound having the structure:
or a pharmaceutically acceptable salt thereof;
wherein
X and Z are members independently selected from O, S and NR 23
wherein
R 23 is a member selected from H, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, and acyl;
R 1 is H, substituted or unsubstituted lower alkyl, or C(O)R 8 , wherein R 8 is a member selected from NR 9 R 10 and OR 9 ,
in which
R 9 , and R 10 are members independently selected from H, substituted or unsubstituted alkyl and substituted or unsubstituted heteroalkyl;
R 2 is CH 3 ;
R 11 is C(O)NR 12 R 13
in which
R 12 , and R 13 are members independently selected from H, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl and substituted or unsubstituted aryl, and at least one of R 12 and R 13 comprises a cleaveable group;
R 4 and R 5 are members independently selected from H, substituted or unsubstituted alkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocycloalkyl, halogen, NO 2 , NR 15 R 16 , NC(O)R 15 , OC(O)NR 15 R 16 , OC(O)OR 15 , C(O)R 15 , OR 15
wherein
R 15 and R 16 are independently selected from H, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocycloalkyl and substituted or unsubstituted peptidyl, wherein R 15 and R 16 together with the nitrogen atom to which they are attached are optionally joined to form a substituted or unsubstituted heterocycloalkyl ring system having from 4 to 6 members, optionally containing two or more heteroatoms; and
X 1 is a leaving group.
5. The compound according to claim 1 , wherein R 1 is CO 2 CH 3 , and R 2 is CH 3 .
6. The compound according to claim 5 , wherein R 4 and R 5 are members independently selected from H, halogen, NH 2 , O(CH 2 ) 2 NMe 2 and NO 2 .
7. The compound according to claim 1 , wherein at least one of R 4 , R 5 , R 15 and R 16 comprises a cleaveable disulfide group.
8. A compound having the structure:
or a pharmaceutically acceptable salt thereof;
wherein
X and Z are members independently selected from O, S and NR 23
wherein
R 23 is a member selected from H, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, and acyl;
R 1 is H, substituted or unsubstituted lower alkyl, or C(O)R 8 , wherein R 8 is a member selected from NR 9 R 10 and OR 9 ,
in which
R 9 , and R 10 are members independently selected from H, substituted or unsubstituted alkyl and substituted or unsubstituted heteroalkyl;
R 2 is H, or substituted or unsubstituted lower alkyl;
R 11 is C(O)NR 12 R 13
in which
R 12 , and R 13 are members independently selected from H, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl and substituted or unsubstituted aryl, and at least one of R 12 and R 13 comprises a cleaveable group;
R 4 and R 5 are members independently selected from H, substituted or unsubstituted alkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocycloalkyl, halogen, NO 2 , NR 15 R 16 , NC(O)R 15 , OC(O)NR 15 R 16 , OC(O)OR 15 , C(O)R 15 , OR 15
wherein
R 15 and R 16 are independently selected from H, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted aryl substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocycloalkyl and substituted or unsubstituted peptidyl, wherein R 15 and R 16 together with the nitrogen atom to which they are attached are optionally joined to form a substituted or unsubstituted heterocycloalkyl ring system having from 4 to 6 members, optionally containing two or more heteroatoms, wherein at least one of R 4 , R 5 , R 15 and R 16 comprises:
wherein
R 30 is a member selected from H, substituted or unsubstituted alkyl and substituted or unsubstituted heteroalkyl;
R 31 and R 32 are members independently selected from H, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted aryl and substituted or unsubstituted heteroaryl, or R 31 and R 32 together are:
wherein
R 33 and R 34 are members independently selected from H, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted aryl and substituted or unsubstituted heteroaryl;
R 35 is a member selected from substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl and NR 36
wherein
R 36 is a member selected from H, substituted or unsubstituted alkyl and substituted or unsubstituted heteroalkyl; and
X 5 is a single bond, O or NR 37
wherein R 37 is a member selected from H, substituted or unsubstituted alkyl and substituted or unsubstituted heteroalkyl; and
X 1 is a leaving group.
9. The compound according to claim 8 , wherein at least one of R 31 , R 32 , R 33 and R 34 is substituted with a member selected from protected or unprotected reactive functional groups targeting agents and detectable labels.
10. The compound according to claim 9 , wherein said targeting agent is an antibody.
11. A compound having the structure:
or a pharmaceutically acceptable salt thereof;
wherein
X and Z are members independently selected from O, S and NR 23
wherein
R 23 is a member selected from H, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, and acyl;
R 1 is H, substituted or unsubstituted lower alkyl, or C(O)R 8 , wherein R 8 is a member selected from NR 9 R 10 and OR 9 ,
in which
R 9 , and R 10 are members independently selected from H, substituted or unsubstituted alkyl and substituted or unsubstituted heteroalkyl;
R 2 is H, or substituted or unsubstituted lower alkyl;
R 11 is a peptidyl moiety having the structure:
wherein
X 3 is a member selected from protected or unprotected reactive functional groups, detectable labels and targeting agents;
L 1 is a linker selected from substituted or unsubstituted alkyl and substituted or unsubstituted heteroalkyl groups;
AA 1 , AA b and AA b+1 are members independently selected from natural and unnatural α-amino acids;
L 2 is a linker selected from substituted or unsubstituted alkyl and substituted or unsubstituted heteroalkyl groups;
q and v are integers independently selected from 0 and 1; and b is an integer from 0 to 20;
R 4 and R 3 are members independently selected from H, substituted or unsubstituted alkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocycloalkyl, halogen, NO 2 , NR 15 R 16 , NC(O)R 15 , OC(O)NR 15 R 16 , OC(O)OR 15 , C(O)R 15 , OR 15
wherein
R 15 and R 16 are independently selected from H, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocycloalkyl and substituted or unsubstituted peptidyl, wherein R 15 and R 16 together with the nitrogen atom to which they are attached are optionally joined to form a substituted or unsubstituted heterocycloalkyl ring system having from 4 to 6 members, optionally containing two or more heteroatoms; and
X 1 is a leaving group.
12. The compound according to claim 11 , wherein at least one of R 4 and R 5 is other than a member selected from H and OCH 3 .
13. The compound according to claim 11 , wherein at least one member selected from R 4 , R 5 , R 15 and R 16 comprises a targeting agent or a detectable label.
14. The compound according to claim 13 , wherein said targeting agent is an antibody.
15. The compound according to claim 5 , wherein X is O; and Z is O.
16. A compound having the structure:
or a pharmaceutically acceptable salt thereof;
wherein
X and Z are members independently selected from O, S and NR 23
wherein
R 23 is a member selected from H, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, and acyl;
R 1 is H, substituted or unsubstituted lower alkyl, or C(O)R 8 , wherein R 8 is a member selected from NR 9 R 10 and OR 9 ,
in which
R 9 , and R 10 are members independently selected from H, substituted or unsubstituted alkyl and substituted or unsubstituted heteroalkyl;
R 2 is H, or substituted or unsubstituted lower alkyl;
R 11 is C(O)NR 12 R 13
in which
R 12 , and R 13 are members independently selected from H, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl and substituted or unsubstituted aryl, and at least one of R 12 and R 13 comprises a cleaveable group:
R 4 and R 5 are members independently selected from H, substituted or unsubstituted alkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocycloalkyl, halogen, NO 2 , NR 15 R 16 , NC(O)R 15 , OC(O)NR 15 R 16 , OC(O)OR 15 , C(O)R 15 , OR 15
wherein
R 15 and R 16 are independently selected from H, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocycloalkyl and substituted or unsubstituted peptidyl, wherein R 15 and R 16 together with the nitrogen atom to which they are attached are optionally joined to form a substituted or unsubstituted heterocycloalkyl ring system having from 4 to 6 members, optionally containing two or more heteroatoms,
wherein a member selected from R 4 and R 5 is:
wherein
X 2 and Z 1 are members independently selected from O, S and NR 3 ;
R 17 and R 18 are members independently selected from H, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocycloalkyl, halogen, NO 2 , NR 19 R 20 , NC(O)R 19 , OC(O)NR 19 , OC(O)OR 19 , C(O)R 19 , OR 19 ,
wherein
R 19 and R 20 are independently selected from substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted peptidyl, wherein R 19 and R 20 together with the nitrogen atom to which they are attached are optionally joined to form a substituted or unsubstituted heterocycloalkyl ring system having from 4 to 6 members, optionally containing two or more heteroatoms; and
X 1 is a leaving group.
17. The compound according to claim 16 , wherein X 2 is O; and Z 1 is a member selected from O and NR 23 .
18. The compound according to claim 11 , wherein said peptidyl moiety has the structure:
wherein
R 21 and R 22 are members independently selected from H, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocycloalkyl, detectable labels and targeting agents;
R 25 is a members selected from H, substituted or unsubstituted lower alkyl, an amino acid side chain, detectable labels, and targeting agents; and
s is an integer from 0 to 20.
19. The compound according to claim 18 , wherein b is an integer from 1 to 5.
20. A compound having the structure:
or a pharmaceutically acceptable salt thereof;
wherein
X and Z are members independently selected from O, S and NR 23
wherein
R 23 is a member selected from H, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, and acyl;
R 1 is H, substituted or unsubstituted lower alkyl, or C(O)R 8 , wherein R 8 is a member selected from NR 9 R 10 and OR 9 ,
in which
R 9 , and R 10 are members independently selected from H, substituted or unsubstituted alkyl and substituted or unsubstituted heteroalkyl;
R 2 is H, or substituted or unsubstituted lower alkyl;
R 11 is C(O)NR 12 R 13
in which
R 12 , and R 13 are members independently selected from H, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl and substituted or unsubstituted aryl, and at least one of R 12 and R 13 comprises a cleaveable group;
R 4 and R 5 are members independently selected from H, substituted or unsubstituted alkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocycloalkyl halogen, NO 2 , NR 15 R 16 , NC(O)R 15 , OC(O)NR 15 R 16 , OC(O)OR 15 , C(O)R 15 , OR 15
wherein
R 15 and R 16 are independently selected from H, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocycloalkyl and substituted or unsubstituted peptidyl, wherein R 15 and R 16 together with the nitrogen atom to which they are attached are optionally joined to form a substituted or unsubstituted heterocycloalkyl ring system having from 4 to 6 members, optionally containing two or more heteroatoms, wherein at least one member selected from R 15 and R 16 has the structure:
wherein
X 4 is member selected from protected or unprotected reactive functional groups, detectable labels and targeting agents;
L 3 is a linker selected from substituted or unsubstituted alkyl and substituted or unsubstituted heteroalkyl groups;
AA 1 , and AA c are members independently selected from natural and unnatural α-amino acids;
L 4 is a linker selected from substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl groups, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, and substituted or unsubstituted cycloalkyl;
R 24 is a member selected from H, substituted or unsubstituted alkyl and substituted or unsubstituted heteroalkyl groups;
p and t are integers independently selected from 0 and 1; and c is an integer from 0 to 20;
X 1 is a leaving group; and
wherein represents a point at which R 15 or R 16 is attached to a remainder of the compound.
21. The compound according to claim 20 , wherein said member has the structure:
wherein
R 27 and R 28 are members independently selected from H, substituted or unsubstituted lower alkyl, amino acid side chains, detectable labels and targeting agents; and
s is an integer in the range of 0 to 6.
22. The compound according to claim 20 , wherein c is an integer from 1 to 5.
23. The compound according to claim 11 or 20 , wherein said detectable label is a fluorophore.
24. The compound according to claim 11 or 20 , wherein said targeting agent is a biomolecule.
25. The compound according to claim 24 , wherein said biomolecule is a member selected from antibodies, receptors, peptides, lectins, saccharides, nucleic acids and combinations thereof.
26. The compound according to claim 18 , wherein at least one of R 21 and R 22 bears a reactive functional group appropriate for conjugating said compound to another molecule.
27. The compound according to claim 26 wherein at least one of R 21 and R 22 is a member selected from substituted alkyl and substituted heteroalkyl, said member having said reactive functional group at its free terminus.
28. The compound according to claim 26 , wherein said compound is conjugated to said another molecule via said reactive functional group.
29. A pharmaceutical formulation comprising a compound according to claim 15 and a pharmaceutically acceptable carrier.
30. A method of killing a cell, said method comprising administering to said cell an amount of a compound according to claim 11 sufficient to kill said cell.
31. A method of killing a carcinoma cell in a subject bearing said cell, said method comprising administering to said subject an amount of a compound according to claim 11 , sufficient to kill said cell.
32. A method of retarding or stopping the growth a tumor in a mammalian subject, said method comprising administering to said subject an amount of a compound according to claim 11 , sufficient to retard or stop said growth.